At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 268 enrolled
Drug / intervention
Desmopressin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablet for the Treatment of Nocturia in Adult Females
In Brief
A Phase 3 clinical trial evaluating Desmopressin and Placebo for Nocturia. Completed, enrolled 268 participants across 45 sites in 2 countries.
Detailed Summary
A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with nocturia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNocturia
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartNov 2010
Primary CompletionNov 2011
TodayJul 2026
First PostedOct 19, 2010
Enrollment StartNov 1, 2010
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.7 years ago
Interventions
Desmopressindrug
Placebodrug